Octapharma AG - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Octapharma AG required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Octapharma AG in the form of a SWOT analysis
• An in-depth view of the business model of Octapharma AG including a breakdown and examination of key business segments
• Intelligence on Octapharma AG’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Octapharma AG, such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Octapharma (or 'the group') is engaged in research and development of human proteins for various therapeutic areas. The group operates in Europe, North and South Americas, Asia Pacific and the Middle East. It is headquartered in Lachen, Switzerland, and employed 5,683 people as on December 31, 2014. The group recorded revenues of E1,279.6 million (approximately $1,700.6 million) during the financial year ended December 2014 (FY2014), an increase of 10.9% over FY2013. The operating profit of the group was E271.2 million (approximately $360.4 million) in FY2014, an increase of 80.9% over FY2013. The net profit of the group was E236.1 million (approximately $313.8 million) in FY2014, an increase of 89.8% over FY2013.

Reasons to Purchase:

• Gain understanding of Octapharma AG and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions
• Assess Octapharma AG as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Octapharma AG’s business structure, strategy and prospects